Status of Lung Cancer Data Collection in Europe

Rich, Anna; Beckett, Paul; Baldwin, David S.

doi:10.1200/cci.17.00052

Cited by 5 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stage I disease is ideally treated with surgical resection, preferentially video-assisted thoracoscopic surgery lobectomy; the best outcomes are associated with an R0 resection [4,[36][37][38][39]. Despite this, surgery rates have fallen in Europe and the U.S. in recent years (but not in England and Wales) [40,41]. Where MDTs are currently employed in surgical decision making, two possible explanations for this decline arise: an MDT might conclude that surgery is clinically inappropriate based on patient characteristics (such as comorbidities) and recommend other treatments [15]; alternatively, patients who are borderline unfit or unwilling to undergo surgery may choose a less invasive treatment option.…”

Section: Stage I Nsclc: Surgery Versus Sbrtmentioning

confidence: 99%

Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach

et al. 2020

View full text Add to dashboard Cite

Non‐small cell lung cancer (NSCLC) accounts for approximately one in five cancer‐related deaths, and management requires increasingly complex decision making by health care professionals. Many centers have therefore adopted a multidisciplinary approach to patient care, using the expertise of various specialists to provide the best evidence‐based, personalized treatment. However, increasingly complex disease staging, as well as expanded biomarker testing and multimodality management algorithms with novel therapeutics, have driven the need for multifaceted, collaborative decision making to optimally guide the overall treatment process. To keep up with the rapidly evolving treatment landscape, national‐level guidelines have been introduced to standardize patient pathways and ensure prompt diagnosis and treatment. Such strategies depend on efficient and effective communication between relevant multidisciplinary team members and have both improved adherence to treatment guidelines and extended patient survival. This article highlights the value of a multidisciplinary approach to diagnosis and staging, treatment decision making, and adverse event management in NSCLC. Implications for Practice This review highlights the value of a multidisciplinary approach to the diagnosis and staging of non‐small cell lung cancer (NSCLC) and makes practical suggestions as to how multidisciplinary teams (MDTs) can be best deployed at individual stages of the disease to improve patient outcomes and effectively manage common adverse events. The authors discuss how a collaborative approach, appropriately leveraging the diverse expertise of NSCLC MDT members (including specialist radiation and medical oncologists, chest physicians, pathologists, pulmonologists, surgeons, and nursing staff) can continue to ensure optimal per‐patient decision making as treatment options become ever more specialized in the era of biomarker‐driven therapeutic strategies.

show abstract

Section: Stage I Nsclc: Surgery Versus Sbrtmentioning

confidence: 99%

Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Also, only a minority of cancer registries can provide sufficient data for the calculation of parameters necessary for the assessment of outcomes and quality of care [69]. • In a 2015 survey, only 6 countries -Denmark, Germany, Hungary, the Netherlands, Slovenia, and United Kingdomreported a lung cancer data collection, or audit, programme in addition to a cancer registry [70,71]. The creation of a pan-European dataset is a significant challenge but will expose variation in practice, identify best practices, show where improvement is needed, and guide investment in resources.…”

Section: Cancer Registration and Data Availabilitymentioning

confidence: 99%

European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer

et al. 2020

View full text Add to dashboard Cite

European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC) are written by experts representing all disciplines involved in cancer care in Europe. They give patients, health professionals, managers and policymakers a guide to essential care throughout the patient journey. Lung cancer is the leading cause of cancer mortality and has a wide variation in treatment and outcomes in Europe. It is a major healthcare burden and has complex diagnosis and treatment challenges. Care must only be carried out in lung cancer units or centres that have a core multidisciplinary team (MDT) and an extended team of health professionals detailed here. Such units are far from universal in European countries. To meet European aspirations for comprehensive cancer control, healthcare organisations must consider the requirements in this paper, paying particular attention to multidisciplinarity and patient-centred pathways from diagnosis, to treatment, to survivorship.

show abstract

“…Several international data-sharing networks have recently emerged to help researchers get access to clinical and genomic data in genomic cancer medicine. For examples, international networks such as PCORnet, 6 OHDSI Research Network, 7 GENIE, 8 BRCA Exchange from GA4GH7, 9 CancerLinQ, 10 ORIEN, 11 and ICGC ARGO, 12 and European networks such as Europe lung cancer data collection 13 and the German Cancer Consortium (DKTK) 14 are some important initiatives in this field. Although such initiatives are interesting, access to full data is restricted to consortium members or lacks relevant clinical information to link genomic alterations with clinical benefit under specific drugs.…”

Section: Introductionmentioning

confidence: 99%

OSIRIS: A Minimum Data Set for Data Sharing and Interoperability in Oncology

Guérin

Laizet

Texier

et al. 2021

JCO Clinical Cancer Informatics

View full text Add to dashboard Cite

PURPOSE Many institutions throughout the world have launched precision medicine initiatives in oncology, and a large amount of clinical and genomic data is being produced. Although there have been attempts at data sharing with the community, initiatives are still limited. In this context, a French task force composed of Integrated Cancer Research Sites (SIRICs), comprehensive cancer centers from the Unicancer network (one of Europe's largest cancer research organization), and university hospitals launched an initiative to improve and accelerate retrospective and prospective clinical and genomic data sharing in oncology. MATERIALS AND METHODS For 5 years, the OSIRIS group has worked on structuring data and identifying technical solutions for collecting and sharing them. The group used a multidisciplinary approach that included weekly scientific and technical meetings over several months to foster a national consensus on a minimal data set. RESULTS The resulting OSIRIS set and event-based data model, which is able to capture the disease course, was built with 67 clinical and 65 omics items. The group made it compatible with the HL7 Fast Healthcare Interoperability Resources (FHIR) format to maximize interoperability. The OSIRIS set was reviewed, approved by a National Plan Strategic Committee, and freely released to the community. A proof-of-concept study was carried out to put the OSIRIS set and Common Data Model into practice using a cohort of 300 patients. CONCLUSION Using a national and bottom-up approach, the OSIRIS group has defined a model including a minimal set of clinical and genomic data that can be used to accelerate data sharing produced in oncology. The model relies on clear and formally defined terminologies and, as such, may also benefit the larger international community.

show abstract

Status of Lung Cancer Data Collection in Europe

Cited by 5 publications

References 29 publications

Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach

Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach

European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer

OSIRIS: A Minimum Data Set for Data Sharing and Interoperability in Oncology

Contact Info

Product

Resources

About